Pharmaceutical Industry Residency Program

Pharmaceutical Industry Residency Program (PIRP)

The Pharmaceutical Industry Residency Program, formerly named the Industrial Pharmacy Residency Program, is administered by the Leslie Dan Faculty of Pharmacy, University of Toronto, in cooperation with participating Pharmaceutical Companies as listed below. These one or two year specialty residencies develop critical knowledge and skills and provide experience within the stated functional area. This is a national educational residency program for graduates from a recognized Pharmacy degree program; it is not an application for a position with a pharmaceutical company.
 

Pharmaceutical Industry Residency Program (PIRP) Information Night

A virtual information session will be held on Wednesday, August 12, 2026, 6:00–7:30 p.m. EST, online via Zoom, to provide an opportunity to learn more about the PIRP and the application process.  

Register

Registration will close August 7.
 

Certification

Over the last few years, many residents and company supervisors have communicated a desire to formally certify the program and we are excited to announce that we have successfully achieved program certification through the Leslie Dan Faculty of Pharmacy, University of Toronto.

Current residents are eligible for the certificate provided they complete the requirements outlined in the terms of reference.

The Leslie Dan Faculty of Pharmacy will continue to support PIRP’s ability to provide high, quality, experiential learning through:

• Skills and educational webinars and exposure to pharmaceutical industry experts
• Resume and interview skills workshops
• Opportunity to network with PIRP residents and pharmaceutical industry professionals
• Participation in a new mentoring program with a PIRP graduate
• Collaboration with and guidance from University of Toronto faculty liaisons
• Coordination to address issues and ensure program requirements are met
   

PIRP Fees 

To help fund this program, starting in the 2027–28 cycle the program fees are as follows: 
Pharmaceutical company fees based on the number of residency positions offered: 

Applicant and resident non-refundable fees: 

• $250 at application (Due September) 
• $2250 once successfully matched with a company (Due August) 
• $2500 payable three months after residency employment starts (Due November) 
  
  

Applications Process

Applications for the 2027–2028 program will open in the Fall 2026. Information for the 2027–2028 application cycle will be posted on this page as it becomes available in July/August, 2026.

For questions, please contact: pharm.residency@utoronto.ca. 
 

Key Dates for 2026-27 Residency Application Cycle 

The Product Development Regulatory and Annual Product Quality Review residencies with Roche, and the residencies with AstraZeneca will be 24 months in length. Please review the updated Terms of Reference document for more information.
 

2026-2027 Residency Program Participating Companies & Specialties 

1. Abbvie: Market Access, Immunology and Oncology 
2. Amgen: Medical Information and Medical Affairs | Value, Market Access & Policy
3. Alexion AstraZeneca: Global Medical Information and Medical Review
4. AstraZeneca: Global Clinical Development, Oncology | Market Access 
5. Bayer: Medical Affairs, Oncology | Market Access
6. BioGen: Market Access, Rare Disease
7. Boehringer Ingelheim: Medical Affairs, Oncology and Mental Health | Medical Affairs, Inflammation  
8. Eisai: Medical Affairs, Oncology and Neurology 
9. Gilead: Medical Affairs, HIV and Oncology
10. Lilly: Medical Affairs, Medical Information | Medical Affairs, Oncology | Market Access, Pricing and Reimbursement 
11. Sanofi: Medical Affairs, Oncology | Medical Affairs, Rare Diseases | Medical Affairs, Immunology | Medical Affairs, Dermatology | Medical Affairs, Respirology | Medical Affairs, Gastrointestinal and Nasal Polyps | Medical Affairs Operations and Transformation | Medical Affairs, Vaccines | Medical Affairs, General Medicine | Market Access, Dupixent | Market Access, General Medicine | Market Access, Oncology and Rare Diseases 
12. Takeda: Medical Affairs, Oncology
13. Medison: Medical Affairs

Download the PIRP Table of Positions 2026-27 below for more information